volume 93, issue 0, P3-P-321 2020
DOI: 10.1254/jpssuppl.93.0_3-p-321
View full text
|
|
Share

Abstract: In CARES clinical trial, febuxostat, a non purine xanthine oxidase inhibitor, was proved non-inferiority the rate of adverse cardiovascular events in patients with gout and major cardiovascular coexisting conditions. In this study, we evaluated the effect of febuxostat on the vascular cell adhesion protein 1 (VCAM-1) induction cultured Human Umbilical Vein Endothelial Cells(HUVEC)were exposed to 24-hour TNF-α (10 ng/mL) treatment. Febuxostat (0.1-100 mM) or solvent was added to the bath medium 20 minutes befor…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals